Reproductive Medicine Centre, Department of Obstetrics and Gynecology, University of Szeged
Szeged, 6724, Hungary
NCT Number: NCT07523022
Men enrolled in the study are assigned to each APHRODITE group. Group 2,3,4 are treated with either gonadotropin preparations or clompihene-citrate (except group 4). The type of the treatment (gonadotropin vs clomiphene) is randomized. After treatment, hormonal measurements, spermiogram and DNA fragmentation tests are repeated, allowing for analysis of the outcome.
Interested in participating?
Request Info18 year and older
Male
Interventional
Phase 4
Szeged, 6724, Hungary
Our research involves male partners of couples suffering from male infertility. After a comprehensive andrological examination, based on the test results, the men are classified into so-called "APHRODITE" categories. Based on these categories, half of the patients are given so-called gonadotropin treatment (the exact treatment depends on the type of category), which involves subcutaneous injections several times a week for a total of 12 weeks. The other half of the patients are recommended oral tablets containing the active ingredient clomiphene citrate, also for 12 weeks. It is important that both types of therapy (gonadotropin and clomiphene citrate) are effective treatments in certain cases of male infertility, according to the literature, so all patients participating in the research receive effective treatment. However, it is decided who receives which treatment by randomization.
After the 12-week treatment, a control sperm analysis and a DNA fragmentation test are performed to determine the success of the treatment (changes in sperm analysis results and DNA fragmentation index).
The improvement in sperm parameters will be determined in the two treatment regimens, the rate of fertilized eggs in subsequent assisted reproduction cycles, the quality of the resulting embryos, and the rate of pregnancies and subsequent losses. The results of the two therapeutic modalities will be compared, so that it can be decided which treatment method is more effective.
The research process is essentially as follows:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
recFSH 3x150NE sc weekly for 12 weeks
Other names: recombinant FSH
hCG 2x5000NE sc weekly for 12 weeks
Other names: human chorionic gonadotropin, choriogonadotropin alfa
clompihene-citrate 50mg p.o. daily for 12 weeks
Other names: CC
Time frame: 12 weeks of treatment
sperm DNA fragmentation Index (%), high DNA stainability (%) are measured and compared to the pretreatment values. Lower numbers mean improvement in this outcome.
Time frame: 12 weeks of treatment
ejaculate volume (ml) after treatment are assessed and compared to the pretreatment values. Higher number means improvement in this outcome.
Time frame: 12 weeks
Sperm concentrations (million/ml) before and after the treatment are compared. Higher number means improvement in this outcome.
Time frame: 12 weeks
Sperm total motility (%), progressive motility (%) after the treatment are compared to the pretreatment values. Higher numbers mean improvement in this outcome.
Time frame: 12 weeks
Total sperm count (million) = ejaculate volume (ml) x sperm concentration (million/ml) and total functional sperm count (million) = total sperm count x progressive motility x 100 are compared before and after the treatment. Higher numbers mean improvement in this outcome.
Time frame: 12 weeks
Percent of normal sperm morphology (%) is counted after the treatment and compared to the pretreatment result. Higher number mean improvement in this outcome.
Time frame: 12 weeks of treatment
in the APHRODITE 2 and 3 groups, the results of the gonadotropin and clomiphene-citrate arms are compared regarding the percent of patients with improvement in total sperm count (million) and total functional sperm count (million)
Time frame: 12 weeks
in the APHRODITE 2 and 3 groups, the results of the gonadotropin and clomiphene-citrate arms are compared regarding the percent of patients with improvement in DNA fragmentation Index (%) and high DNA stainability (%)
Time frame: 12 weeks
in the APHRODITE 2 and 3 groups, the results of the gonadotropin and clomiphene-citrate arms are compared regarding the percent of patients with improvement in total sperm motility (%) and progressive sperm motility (%)
Time frame: 12 weeks
in the APHRODITE 2 and 3 groups, the results of the gonadotropin and clomiphene-citrate arms are compared regarding the percent of patients with improvement in normal sperm morphology (%)
Time frame: 12 weeks of treatment
serum FSH (IU/l), LH (IU/l) are measured after the treatment and compared to the pretreatment values.
Time frame: 12 weeks
Total testosterone (nmol/l) is measured after the treatment and compared to the pretreatment values.
Time frame: 12 weeks
Estradiol (pmol/l) are measured after the treatment and compared to the pretreatment results
Szeged University
Other
Acronym: GONACLO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07265908
Female Infertility, Female Urogenital Diseases
Milan, Italy
View Trial DetailsNCT07740161
Genital Diseases, Genital Diseases, Male
Las Vegas, Nevada, United States
View Trial DetailsNCT07684339
Genital Diseases, Genital Diseases, Male
Abu Dhabi, United Arab Emirates
View Trial DetailsNCT07684963
Cardiovascular Diseases, Genital Diseases
View Trial Details